Name
GS1-07 - Adjuvant palbociclib in HR+/HER2- early breast cancer: Final protocol-planned analysis results from 5,761 patients in the randomized phase III PALLAS trial
Date & Time
Tuesday, December 7, 2021
Speakers
Virtual Session Link